The effect of kidney function on guideline‐directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cardiology"
DOI: 10.1002/clc.24244
Abstract: Kidney dysfunction (KD) is a main limiting factor of applying guideline‐directed medical therapy (GDMT) and reaching the recommended target doses (TD) in heart failure (HF) with reduced ejection fraction (HFrEF). read more here.
Keywords: reduced ejection; medical therapy; failure reduced; guideline directed ... See more keywords
Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12569
Abstract: The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European… read more here.
Keywords: heart; heart failure; management; reduced ejection ... See more keywords
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13237
Abstract: Failure to prescribe key medicines at evidence‐based doses is associated with increased mortality and hospitalization for patients with Heart Failure with reduced Ejection Fraction (HFrEF). We assessed titration patterns of guideline‐recommended HFrEF medicines internationally and… read more here.
Keywords: heart failure; reduced ejection; failure reduced; patients heart ... See more keywords
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13313
Abstract: This study aimed to determine the effects of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of SGLT2i with angiotensin receptor neprilysin inhibitor (ARNI), and find whether combination… read more here.
Keywords: ejection fraction; heart; heart failure; reduced ejection ... See more keywords
Neutrophils pro‐inflammatory and anti‐inflammatory cytokine release in patients with heart failure and reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13539
Abstract: Heart failure with reduced ejection fraction (HFrEF) is characterized by sub‐clinical inflammation. Changes in selected biomarkers of inflammation concomitant with the release of pro‐inflammatory and anti‐inflammatory cytokines by neutrophils have not been investigated in patients… read more here.
Keywords: ejection fraction; heart; heart failure; reduced ejection ... See more keywords
The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13940
Abstract: We evaluated the clinical outcomes and trajectory of cardiac reverse remodelling according to the timing of sacubitril/valsartan (Sac/Val) use in patients with heart failure (HF) with reduced ejection fraction (HFrEF). read more here.
Keywords: sacubitril valsartan; heart failure; failure reduced; heart ... See more keywords
Modified reverse shock index predicts early outcomes of heart failure with reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14031
Abstract: Increased blood pressure (BP) and decreased heart rate (HR) are signs of stabilization in patients admitted for acute HF. Changes in BP and HR during admission and their correlation with outcomes were assessed in hospitalized… read more here.
Keywords: heart failure; failure reduced; ejection fraction; heart ... See more keywords
Treatment response in recent‐onset heart failure with reduced ejection fraction: non‐ischaemic vs. ischaemic aetiology
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14214
Abstract: In heart failure (HF) with reduced left ventricular ejection fraction (HFrEF), the prognosis appears better in non‐ischaemic than in ischaemic aetiology. Infrequent diagnostic work‐up for ischaemic heart disease (IHD) in HF is reported. In this… read more here.
Keywords: heart failure; non ischaemic; failure reduced; heart ... See more keywords
Circulating 3‐hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2024 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14476
Abstract: In patients with chronic heart failure with reduced ejection fraction (HFrEF), myocardial ketone metabolism is increased and short‐term treatment with the ketone body 3‐hydroxy butyrate (3‐OHB) has beneficial haemodynamic effects. In patients with HFrEF, we… read more here.
Keywords: chronic heart; heart; failure reduced; patients chronic ... See more keywords
Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2024 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14700
Abstract: We aim to explore the associations between serum tyrosine (Tyr) to threonine (Thr) ratio and chronic heart failure (HF) with reduced or mildly reduced ejection fraction (EF) (HFrEF or HFmrEF). read more here.
Keywords: heart; failure reduced; mildly reduced; heart failure ... See more keywords
Comparison of mouse models of heart failure with reduced ejection fraction
Sign Up to like & getrecommendations! Published in 2024 at "ESC Heart Failure"
DOI: 10.1002/ehf2.15031
Abstract: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of death worldwide; thus, therapeutic improvements are needed. In vivo preclinical models are essential to identify molecular drug targets for future therapies. Transverse aortic… read more here.
Keywords: reduced ejection; heart; failure reduced; ejection fraction ... See more keywords